发明名称 |
Dosage of oligonucleotides suitable for the treatment of tumors |
摘要 |
A method for preventing and/or treating a tumor, the method comprising: intravenously administering an antisense oligonucleotide in an amount of between about 400 to about 800 mg/m2/treatment cycle, the antisense oligonucleotide comprises 8 to 30 nucleotide building blocks, which hybridizes with mRNA of TGF-beta-2, -1 and/or -3 for the preparation of a pharmaceutical composition. |
申请公布号 |
US8822425(B2) |
申请公布日期 |
2014.09.02 |
申请号 |
US200912453487 |
申请日期 |
2009.05.12 |
申请人 |
Antisense Pharma GmbH |
发明人 |
Schlingensiepen Karl-Hermann;Heinrichs Hubert;Schmaus Susanne |
分类号 |
C12N15/11;C07H21/04 |
主分类号 |
C12N15/11 |
代理机构 |
Jacobson Holman, PLLC. |
代理人 |
Jacobson Holman, PLLC. |
主权项 |
1. A method for treating pancreatic carcinoma or malignant melanoma consisting of: intravenously administering only an antisense oligonucleotide of sequence SEQ ID NO: 22 in an amount of between about 400 to about 800 mg/m2/treatment cycle, wherein a treatment cycle consists of an administration cycle that is the time taken for a first administration of about 400 to about 800 mg/m2 of the oligonucleotide, and, if any further administration cycle is performed, the time interval between consecutive administration cycles. |
地址 |
Regensburg DE |